mph Bangladesh


Cefotaxime

(sef oh taks' eem)

PCaution when used during lactation : Caution when used during pregnancy

LCaution when used during lactation : Caution when used during lactation

Molecule Info

 

 | See TERMINOLOGY & ABBREVIATIONS |
Indication(s) & Dosage

Parenteral route
Septicaemia
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Skin and skin structure infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Central nervous system infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Bacteraemia
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Bone and joint infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Genitourinary infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Gynaecological infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Intra-abdominal infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Lower respiratory tract infections
Adult: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes. Max: 12 g daily. 
Child: â‰¤1 mth: 50 mg/kg/dose, given every 8-12 hr; 1 mth-12 yr and <50 kg: 50-180 mg/kg/day, given in 4-6 equally divided doses. Higher doses may be used in more severe infections. ≥50 kg: 1-2 g every 4-12 hr depending on the severity of the infection. May be given via deep IM inj or slow IV inj over 3-5 minutes or by IV infusion over 20-60 minutes.
Max Dosage: Adult: 12 g.

Prophylaxis of surgical infections
Adult: 1 g, given 30-90 minutes before surgery. May be given via IM or IV inj or infusion. 

Gonorrhoea
Adult: A single dose of 0.5-1 g, given via IM inj or slow IV inj or infusion.

Renal impairment: Dose reduction is necessary.
Special Populations: In renal impairment with CrCl of ≤5 mg/min, cefotaxime dose is reduced by 50%. Treatment is continued for up to 72 hr after relief of symptoms and for at least 10 days in Group A beta-haemolytic streptococcal infections.

Contraindications Hypersensitivity to cephalosporins.
Special Precautions History of penicillin allergy; colitis; impaired renal function; pregnancy, lactation.
Adverse Drug Reaction(s) Pain at inj site; hypersensitivity reactions, rash, pruritus; diarrhoea, nausea, vomiting; candidiasis; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
Potentially Fatal: Anaphylactic reaction; nephrotoxicity.
Drug Interactions Probenecid decreases cefotaxime elimination.
Potentially Fatal: Nephrotoxicity with furosemide and aminoglycosides. Please consult detailed drug interactions before prescribing.
Lab Interference False-positive result for urine-glucose, serum or urine creatinine with Jaffe reaction.
Pregnancy Category (US FDA) Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters).
Storage Parenteral: Store below 30°C.
Pharmacology Cefotaxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption: Rapidly absorbed (IM); peak plasma concentrations after 30 min (IM), 4 hr (IV).
Distribution: Widely distributed into body tissues and fluids; CSF (therapeutic concentrations, esp when the meninges are inflamed). Crosses the placenta and enters breast milk. Protein-binding: 40%.
Metabolism: Hepatic (partial); converted to desacetylcefotaxime and inactive metabolites.
Excretion: Mainly by the kidneys via the urine (40% as unchanged drug within 24 hr); further 20% as desacetylcefotaxime. Removed by haemodialysis.
ATC Classification J01DD01 - cefotaxime.

Brand/Product Info


Total Products : 13             
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
CEFOT ACI Ltd. Cefotaxime sodium USP 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 50.00, 76.00 & 132.00 MRP
CEFOT I/V ACI Ltd. Cefotaxime sodium USP 2gm (I/V) Injection 2gm vial: 250.00 MRP
CEFOTAX Renata Limited Cefotaxime sodium USP 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 50.19, 76.29 & 132.50 MRP
Cefotime 1 gm Incepta Pharmaceuticals Limited Cefotaxime 1 gm (as Cefotaxime Sodium BP) Injection 1x1's:MRP 132 Tk
Cefotime 250 Incepta Pharmaceuticals Limited Cefotaxime 250mg (as Cefotaxime Sodium BP) Injection 1x1's:MRP 50 Tk
Cefotime 500 Incepta Pharmaceuticals Limited Cefotaxime 500 mg (as Cefotaxime Sodium BP) Injection 1x1's:MRP 76 Tk
CETAXIM Globe Pharmaceuticals Ltd Cefotaxime sodium USP 500mg & 1gm (IV/IM) Injection 500mg, 1gm vial: 76.00 & 130.00 MRP
MAXCEF 1G Square Pharmaceuticals Ltd. Cefotaxime 1 gm IM/IV Injection 1x1's: 140.42 MRP
MAXCEF 250 Square Pharmaceuticals Ltd. Cefotaxime 250mg IM/IV Injection 1x1's: 70.21 MRP
MAXCEF 500 Square Pharmaceuticals Ltd. Cefotaxime 500mg IM/IV Injection 1x1's: 90.27 MRP
TAXCEPH IBN SINA Pharmaceutical Industry Ltd. Cefotaxime sodium USP 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 52.00, 76.00, 140.00 IP
TAXIM The Acme Laboratories Ltd. Cefotaxime sodium USP 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 50.20 & 76.29 & 132.00 MRP
TORPED Orion Pharma Ltd. Cefotaxime sodium USP 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 50.19,75.28 & 110.49 MRP

Gen. MedInfo

Why is this medication prescribed?

Cefotaxime, an antibiotic, helps treat certain infection. The drug will be either injected into a large muscle (such as your buttock or hip) or added to an intravenous fluid that will drip through a needle or catheter placed in your vein for 30 minutes, two to four times a day.

Cefotaxime eliminates bacteria that cause many kinds of infections, including lung, skin, bone, joint, stomach, blood, gynecological, and urinary tract infections. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Your health care provider (e.g. doctor) may measure the effectiveness and side effects of your treatment using laboratory tests and physical examinations. It is important to keep all appointments with your doctor and the laboratory. The length of treatment depends on how your infection and symptoms respond to the medication.

Precautions

Before administering cefotaxime 

  • tell your doctor if you are allergic to cefotaxime, any other cephalosporin [e.g., cefaclor (Ceclor), cefadroxil (Duricef), or cephalexin (Keflex)], penicillins, or any other drugs.
  • tell your doctor what prescription and nonprescription medications you are taking, especially other antibiotics, probenecid (Benemid), and vitamins.
  • tell your doctor if you have or have ever had kidney, liver, or gastrointestinal disease (especially colitis).
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking cefotaxime, call your doctor.

Administering your medication

Before you administer cefotaxime, look at the solution closely. It should be clear and free of floating material. Gently squeeze the bag or observe the solution container to make sure there are no leaks. Do not use the solution if it is discolored, if it contains particles, or if the bag or container leaks. Use a new solution, but show the damaged one to your health care provider.

It is important that you use your medication exactly as directed. Do not stop your therapy on your own for any reason because your infection could worsen and result in hospitalization. Do not change your dosing schedule without talking to your health care provider. Your health care provider may tell you to stop your infusion if you have a mechanical problem (such as a blockage in the tubing, needle, or catheter); if you have to stop an infusion, call your health care provider immediately so your therapy can continue.

Side effects

Cefotaxime may cause side effects. Tell your health care provider if any of these symptoms are severe or do not go away: 

  • diarrhea

  • stomach pain

  • upset stomach

  • vomiting

If you experience any of the following symptoms, call your health care provider immediately:

  • unusual bleeding or bruising

  • difficulty breathing

  • skin rash

  • itching

  • hives

  • sore mouth or throat

Storing your medication 

  • Your health care provider probably will give you a several-day supply of cefotaxime at a time. If you are receiving cefotaxime intravenously (in your vein), you probably will be told to store it in the refrigerator or freezer.

  • Take your next dose from the refrigerator 1 hour before using it; place it in a clean, dry area to allow it to warm to room temperature.

  • If you are told to store additional cefotaxime in the freezer, always move a 24-hour supply to the refrigerator for the next day's use.

  • Do not refreeze medications.

If you are receiving cefotaxime intramuscularly (in your muscle), your health care provider will tell you how to store it properly.

Store your medication only as directed. Make sure you understand what you need to store your medication properly.

Keep your supplies in a clean, dry place when you are not using them, and keep all medications and supplies out of reach of children. Your health care provider will tell you how to throw away used needles, syringes, tubing, and containers to avoid accidental injury.

In case of emergency/overdose 

In case of overdose, consult your doctor. If the victim has collapsed or is not breathing, consult local medical emergency services.

Signs of infection

If you are receiving cefotaxime in your vein or under your skin, you need to know the symptoms of a catheter-related infection (an infection where the needle enters your vein or skin). If you experience any of these effects near your intravenous catheter, tell your health care provider as soon as possible: 

  • tenderness

  • warmth

  • irritation

  • < p>drainage

  • redness

  • swelling

  • pain

This medication may cause other side effects.  Consult your doctor if you have any unusual problems while taking this.

In case of emergency/overdose

In case of overdose, consult your doctor. If the victim has collapsed or is not breathing, consult local medical emergency services. 

What other information should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to this medicine.

Do not let anyone else use your medication. If you still have symptoms and need further treatment, consult your doctor.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Ref:  U.S. National Library of Medicine.


This information is provided for reference only and not a replacement for and should only be used in conjunction with full consultation with a registered medical practitioner. It may not contain all the available information you require and cannot substitute professional medical care, nor does it take into account all individual circumstances. Although great effort has been made to ensure content accuracy, mph-bd shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.

Simple Breath Test Might Diagnose Heart Failure An experimental breath test, designed to quickly identify patients suffering from heart failure simply by analyzing the contents of a...
Osteoporosis drug stops Breast cancer growth   News & Events News & Events     HIGHLIGHTS Osteoporosis drug stops growth of breast cancer...
Generic drug safety info loophole FDA plans to close generic drug safety info loophole The US Food and Drug Administration has announced plans to speed up the dissemination of...
Large trials unpublished   News & Events News & Events   HIGHLIGHTS Almost 1 in 3 of large clinical trials unpublished after...
TB activists boo Indian minister News & Events News & Events   HIGHLIGHTS TB activists at world conference boo Indian minister off...
Key bone marrow protein identified News & Events News & Events   HIGHLIGHTS Key bone marrow protein identified as potential new leukemia...